BioTime (BTX) and its recently formed subsidiary BioTime Acquisition Corporation announced that they have entered into a definitive Asset Contribution Agreement with Geron Corporation (GERN) to ...
BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...
Paper and Related Patent Filings Are a Strategic Step Forward in the Development of the Company's ReCyte(TM) iPS Technology ALAMEDA, Calif., Mar 16, 2010 (BUSINESS WIRE) -- BioTime, Inc., a ...
BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents™ (http ...
ZKTeco USA, a major provider of biometric verification and access control technology, announced the company has launched its new cloud-based access control software platform, Cielo365 that is changing ...
Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback